Recent Congress Publications
For Boehringer Ingelheim, cancer care is personal - today and for future generations. Our long-term commitment to oncology is to pursue leading science to develop innovative cancer treatments across different tumor types.
Page last updated: December 2025
ESMO Asia 2025
To view ESMO Asia 2025 publications please see the All Congress Publications section
JLCS 2025
To view JLCS 2025 publications please see the All Congress Publications section
NANETS 2025
DAREON®-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Chauhan et al.
ESMO 2025*
Beamion™ BCGC-1: A phase Ib/II, randomized, open-label, multicenter trial of oral zongertinib, alone or in combination, for the treatment of advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)
Author(s): Hurvitz et al.
Ezabenlimab (BI 754091) and induction mDCF (modified docetaxel, cisplatin, and 5-fluorouracil) followed by adaptive chemoradiotherapy in patients with stage III squamous cell anal carcinoma: final results of the Phase II INTERACT-ION study
Author(s): Kim et al.
An open-label, Phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)
Author(s): Laban et al.
Phase Ia results for systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors: progress to date
Author(s): Parkes et al.
Obrixtamig (BI 764532) in patients with relapsed/refractory DLL3-high expressing extrapulmonary neuroendocrine carcinoma: trial in progress of the dose expansion part of the Phase II DAREON®-5 trial
Author(s): Pavel et al.
DAREON®-8: A Phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
DAREON®-9, a Phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients with advanced small cell lung cancer: updated results
Author(s): Wermke et al.
*To view ESMO 2025 NSCLC publications please see the All Congress Publications section
WCLC 2025
To view WCLC 2025 publications please see the All Congress Publications section
ASCO 2025
Beamion™ PANTUMOR-1: a Phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2-mutated or overexpressed/amplified solid tumors
Author(s): Schram et al.
Zongertinib in HER2-altered breast cancer: preclinical activity and preliminary results from a Phase Ia dose-escalation study
Author(s): Berz et al.
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing Phase I trial
Author(s): Capdevila et al.
DAREON®-9, a Phase Ib study of obrixtamig plus topotecan in patients with advanced small cell lung cancer (SCLC): interim analysis results
Author(s): Wermke et al.
An open-label, Phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors
Author(s): Wang et al.
An open-label, Phase Ib trial of the SIRPα inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients with head and neck squamous cell carcinoma
Author(s): Rojas et al.
An open-label, Phase Ib dose-expansion study to assess the efficacy of CD137 FAP agonist BI 765179 plus pembrolizumab as first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)–positive head and neck squamous cell carcinoma (HNSCC)
Author(s): Shroff et al.
AACR 2025
Absorption, distribution, metabolism, and excretion (ADME) properties and absolute bioavailability of zongertinib, a selective oral HER2-specific tyrosine kinase inhibitor, in healthy male subjects
Author(s): Joseph et al.
The effect of food on zongertinib plasma exposure in healthy volunteers
Author(s): Pereira et al.
An open-label, Phase Ib, dose-expansion study to assess the efficacy of CD137 FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent, programmed cell death ligand-1 (PD-L1)-positive, head and neck squamous cell carcinoma (HNSCC)
Author(s): Shroff et al.
ASCO GI 2025
Beamion™ BCGC-1: a Phase Ib dose-escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)
Author(s): Nakayama et al.
ESMO Breast 2025
Beamion™ BCGC-1: a Phase Ib/II dose escalation/optimization, randomized, open-label trial of oral zongertinib alone or in combination for advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)
Author(s): Hurvitz et al.
ESMO GI 2025
Zongertinib in HER2-altered gastrointestinal cancers: preclinical activity and clinical findings from a Phase Ia study
Author(s): Yoh et al.
